FDA Issues Final Rule Aligning Quality System Management Regulation (QMSR) with ISO 13485:2016

On January 31, 2024, the U.S. Food and Drug Administration (FDA) introduced a significant regulatory update through the issuance of the final rule for the Quality Management System Regulation (QMSR). This rule is aims to align the existing United States’ Quality System (QS) Regulation, as outlined in 21 CFR 820, with the internationally recognized ISO 13485:2016 standard for medical devices – Quality management systems – requirements for regulatory purposes. As a result of this alignment, the revised part of 21 CFR 820 is now referred to as the Quality Management System Regulation (QMSR).

Quality System Management Regulation – Key Amendments and Clarifications

  • Incorporation of ISO 13485:2016 by reference: The FDA’s final rule incorporates the quality management system requirements as outlined in ISO 13485:2016 into the QS Regulation 21 CFR Part 820. by reference. This means that manufacturers will need to comply with the ISO standard as if they were explicitly written within the CFR code. However, it’s essential to note that while ISO 13485:2016 covers general quality management system (QMS) requirements, certain specific provisions, such as those concerning combination products, will remain part of the 21 CFR Part 820. Therefore, manufacturers must adhere to both the integrated ISO 13485:2016 standard and any additional requirements specified within the CFR to ensure compliance.
  • Title Amendment of 21 CFR Part 820: The rule formally amends the title of the regulation to the Quality Management System Regulation (QMSR), reflecting the integration of ISO 13485:2016.
  • Additional Requirements: QMSR introduces supplementary requirements to prevent inconsistencies with other applicable FDA regulations. Conforming edits have been made to clarify the Quality Management System (QMS) requirements for combination products in part 4 of the regulation, without impacting the Current Good Manufacturing Practice (CGMP) requirements for these products.
  • Aligning with International Standards: This regulatory adjustment is part of the FDA’s overarching strategy to align its regulatory framework with international standards. By adopting the ISO 13485:2016 standard, the FDA aims to facilitate the timely introduction of safe, effective, and high-quality medical devices for patients.

QMSR – Implementation and Impact

The FDA has outlined the following aspects related to the implementation and impact of the final rule:

  • Preparation for Harmonization: The FDA intends to engage in various implementation activities, including updating information technology systems, training FDA staff responsible for compliance assessments, developing an inspection process, revising relevant regulations, and communicating changes to stakeholders.
  • Staff Training: FDA staff will undergo training on the final rule, the revised inspection process, and changes to associated policies and procedures. Broader Quality Management System trainings will be deployed within the FDA to familiarize staff with quality management system concepts and requirements.
  • Impact on FDA Staff and Programs: While the FDA will continue its operations to protect public health, the primary impact is expected in internal trainings. Staff will need to acquaint themselves with the new regulation and any updates to procedures, processes, and policies resulting from the change.
  • New Inspection Process: A new inspection process aligned with the QMSR requirements will be developed and implemented when the rule takes effect, two years from publication.
  • Handling Revisions to ISO 13485:2016: Any future revisions to ISO 13485:2016 will be evaluated to determine their impact on the QMSR. If needed, amendments will be implemented through rulemaking.
  • Effective Date of the Rule: The final rule becomes effective two years after publication in the Federal Register, with the FDA enforcing QMSR requirements from February 2, 2026.

Potential Concerns and Considerations for Manufacturers:

  • Impact on Quality Management Systems: Manufacturers currently adhering to both ISO 13485:2016 and 21 CFR Part 820 should proactively conduct a comprehensive assessment. Evaluate how the final rule influences your Quality Management Systems (QMS). Ensure a thorough understanding of the implications on processes, documentation, and compliance requirements.
  • Communication with Regulatory Authorities: Industry stakeholders are encouraged to engage in proactive communication with regulatory authorities to seek clarification on specific requirements related to the rule and to ensure a comprehensive understanding of how the transition to QMSR aligns with existing compliance frameworks.
  • Training and Education: Companies may need to invest in staff training programs to educate personnel on the revised QMSR and/or ISO 13485:2016. This includes understanding the integrated ISO 13485:2016 elements and the retained components from 21 CFR Part 820.

In conclusion, the FDA’s issuance of the QMSR final rule represents a pivotal step toward enhancing the regulatory framework for medical devices globally. The alignment with ISO 13485:2016 underscores FDA’s commitment to global harmonization and promoting consistency in device regulation worldwide. The FDA’s meticulous approach to implementation and impact assessment reflects a dedication to ensuring the continued safety, quality, and effectiveness of medical devices for patients.

PharmOut can help with your Quality Management System – from initial development to ongoing refinement, contact us to discuss.